Pioglitazone

Biochem/physiol Actions PF-6422899 is an alkynylated derivative of PF-6274484: irreversible inhibitor of EGFR kinase activity. PF-6422899 binds covalently to active-site cysteine residues in the ATP binding pocket of EGFR.

Biochem/physiol Actions PF-6422899 is an alkynylated derivative of PF-6274484: irreversible inhibitor of EGFR kinase activity. PF-6422899 binds covalently to active-site cysteine residues in the ATP binding pocket of EGFR.

A full antagonist of estrogen ER&beta receptors with 36-fold selectivity over ER&alpha (relative binding affinities are 0.01 and 0.36, respectively) enhances SKOV3 and OV2008 ovarian cancer cell growth in in vitro assays at 100 pM.

A full antagonist of estrogen ER&beta receptors with 36-fold selectivity over ER&alpha (relative binding affinities are 0.01 and 0.36, respectively) enhances SKOV3 and OV2008 ovarian cancer cell growth in in vitro assays at 100 pM.

InformationPI-103 is a multi-targeted PI3K inhibitor forp110α/β/δ/γwithIC50of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK withIC50of 30 nM/23 nM. PI-103 inducesapoptosisin murine T-cell Lymphoma.In vitroPI-103 potently

Potent and selective PI 3-kinase p110δ inhibitor.

Potent and selective PI 3-kinase p110δ inhibitor.

Potent and selective PI 3-kinase p110δ inhibitor.

Potent and selective PI 3-kinase p110δ inhibitor.

Potent and selective PI 3-kinase p110δ inhibitor.

A potent, selective inhibitor of p110&delta.

A potent, selective inhibitor of p110&delta.